Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir
over a 12-hour dosing interval, following administration to male and female HIV-negative
healthy volunteers of:
1. Lopinavir/ritonavir 400/100 mg twice daily
2. Lopinavir/ritonavir 200/150 mg twice daily
3. Lopinavir/ritonavir 200/50 mg twice daily